Financials
Our markets
In 2024, Alfasigma’s revenues grew 37% YoY to €1.87 billion on the back of both solid organic growth and the successful integration of strategic acquisitions across its portfolio, positioning the Company on track to become a truly global innovative rare disease healthcare company focused on GI and hepatology.
Alfasigma’s growth in 2024 was notably driven by impressive performances across strategic international markets, particularly in China, Eastern Europe the US, and Western Europe.
Turnover
€ 1.87
billions in 2024
Robust Performance
in Strategic Categories
Specialty gastroenterology
Hepatology
Solid Global Growth,
driven by:
• China
• Eastern Europe
• Mexico
• US
• Italy
• Western Europe
Looking ahead, Alfasigma is well-positioned to sustain its dynamic growth trajectory by leveraging its strong product portfolio, pipeline, strategic market presence. The company remains focused on maximizing the potential of its established portfolio, accelerating its innovation pipeline, and pursuing further strategic acquisitions in specialty and rare-disease areas.
Moreover, the company remains focused on identifying further strategic growth opportunities, advancing innovative R&D, and maintaining operational excellence to enhance patient outcomes and solidify its global leadership position.
Headcount
3800
Workforce
24
Countries
Read More
Morpho is a distinctive Contract Development and Manufacturing Organisation (CDMO) of Alfasigma.